MONALISA® Hard Type with Lidocaine – 1 × 1ml *SALE*

MONALISA® Hard Type with Lidocaine – 1 × 1ml

Product Overview

MONALISA® Hard Type with Lidocaine is a professional cross-linked Hyaluronic Acid (HA) dermal filler developed for deeper wrinkle correction, facial volume restoration, structural support and contour enhancement.

Manufactured by GENOSS, MONALISA® Hard Type contains 24mg/ml cross-linked Hyaluronic Acid and 0.3% Lidocaine.

Its firmer gel characteristics are designed to provide greater structural support and projection than softer formulations within the MONALISA® range, making it particularly suited to professional treatments where enhanced facial structure, contour and volume are required.

The cross-linked Hyaluronic Acid gel provides an immediate volumising effect following appropriate placement, helping restore selected areas of facial volume loss and improve the appearance of deeper wrinkles and folds.

Hyaluronic Acid also attracts and retains water within the tissue, supporting hydration and smoothness within the treated area.

The addition of 0.3% Lidocaine, a local anaesthetic, is intended to help reduce injection-related discomfort and improve patient comfort during treatment.

Unlike skin boosters or regenerative Polynucleotide treatments, MONALISA® Hard Type is a structural dermal filler designed primarily for volume restoration, deeper correction, facial contouring and tissue support.

Pack Contents

Each pack contains:

• 1 × 1ml pre-filled syringe of MONALISA® Hard Type with Lidocaine

• Hyaluronic Acid concentration: 24mg/ml

• Lidocaine concentration: 0.3%

• Sterile injection needle(s) as supplied by the manufacturer

• Sterile, sealed professional-use packaging

Total Volume: 1ml

Always check the individual product packaging, manufacturer labelling and current Instructions for Use before administration.

Product CompositionCross-Linked Hyaluronic Acid – 24mg/ml

MONALISA® Hard Type contains highly purified cross-linked Hyaluronic Acid at a concentration of 24mg/ml.

The formulation is designed to provide:

• Structural tissue support

• Facial volume restoration

• Correction of deeper wrinkles and folds

• Improved facial contour

• Gel stability

• Volume retention

• Controlled tissue integration

Cross-linking helps improve the stability and persistence of Hyaluronic Acid within the treated tissue compared with non-cross-linked formulations.

Lidocaine – 0.3%

The formulation contains 0.3% Lidocaine, a local anaesthetic incorporated into the gel to help reduce injection-related discomfort.

Patients with known hypersensitivity to Lidocaine or other relevant product components must be appropriately assessed before treatment.

MONALISA® Filler Technology

MONALISA® dermal fillers are developed using GENOSS's Hyaluronic Acid manufacturing and cross-linking technology to create stable injectable gels with controlled viscoelastic characteristics.

The MONALISA® range incorporates several key product characteristics.

High-Purity Hyaluronic Acid

GENOSS describes the formulation as using high-purity medical or pharmaceutical-grade Hyaluronic Acid produced under controlled manufacturing conditions.

Cross-Linked HA Gel Matrix

The cross-linked gel structure is designed to support gel stability, volume retention and structural performance following appropriate placement.

Viscoelastic Properties

The formulation is designed to provide a balance of elasticity, cohesiveness and tissue integration according to the selected MONALISA® product type.

Ergonomic Syringe Design

GENOSS describes its syringe grip and push rod as being designed to support controlled product delivery and consistent injection force.

Lidocaine-Containing Formulation

The inclusion of 0.3% Lidocaine is intended to improve patient comfort during administration.

MONALISA® Hard Type is positioned as a firmer structural option within the range, developed for treatment requirements involving deeper correction, volume restoration and facial contour enhancement.

Structural Facial Support & Contouring

MONALISA® Hard Type is designed for professional treatment of selected areas where greater structural support or volume is required.

Its firmer cross-linked HA gel is intended to support:

• Facial volume restoration

• Deeper wrinkle and fold correction

• Chin contour enhancement

• Jawline definition

• Cheek and mid-face volume support

• Lower-face contour refinement

• Correction of selected facial asymmetries

The product's suitability for a particular anatomical area must always be confirmed against the manufacturer's current Instructions for Use.

Treatment planning should account for facial anatomy, vascular structures, tissue characteristics, existing facial proportions and individual treatment objectives.

Key Benefits

• Professional cross-linked Hyaluronic Acid dermal filler

• 24mg/ml Hyaluronic Acid concentration

• 0.3% Lidocaine

• Firmer structural gel formulation

• Designed for deeper wrinkle and fold correction

• Supports facial volume restoration

• Provides structural tissue support

• Suitable for appropriate facial contouring protocols

• May support chin shape and projection

• May improve jawline definition

• Supports selected cheek and mid-face volume restoration

• Helps improve the appearance of deeper nasolabial folds

• Provides an immediate volumising effect following appropriate placement

• Cross-linked formulation designed for improved gel stability

• Manufactured using high-purity Hyaluronic Acid

• Lidocaine-containing formulation helps improve treatment comfort

• Ergonomic syringe design supports controlled product delivery

• Supplied in a 1ml pre-filled syringe

• Intended for appropriately qualified professional use

Common Treatment Areas

MONALISA® Hard Type is positioned for areas requiring greater structural support, volume or deeper correction.

Potential professional applications described in the supplied product information include:

• Chin augmentation and projection

• Jawline contouring

• Facial oval and lower-face contouring

• Cheek volume restoration

• Mid-face volume support

• Deep nasolabial folds

• Marionette region where clinically appropriate

• Selected areas of deeper facial volume loss

• Facial contour asymmetry

• Appropriate structural facial enhancement procedures

Treatment area suitability must always be determined following comprehensive assessment of the patient's anatomy, tissue quality, facial proportions and individual treatment objectives.

Only undertake applications supported by the manufacturer's current Instructions for Use and the practitioner's training, competence and applicable professional requirements.

MONALISA® Hard Type vs Softer Dermal Fillers

Different dermal filler formulations are developed for different anatomical areas and treatment objectives.

Softer formulations may be selected where flexibility, subtle correction or more superficial treatment characteristics are required.

MONALISA® Hard Type is positioned as a firmer structural formulation for applications where greater tissue support and projection are desired.

Its primary treatment objectives include:

• Restoring facial volume

• Providing structural support

• Enhancing selected facial contours

• Correcting deeper wrinkles and folds

• Supporting projection in appropriate anatomical areas

The choice of dermal filler should always be based on product characteristics, authorised indications, patient anatomy and professional assessment rather than HA concentration alone.

Professional Treatment Considerations

MONALISA® Hard Type is intended for administration by appropriately qualified and trained professionals with suitable competence in dermal filler treatments and facial anatomy.

Treatment planning should include:

• Comprehensive patient consultation

• Review of medical history

• Assessment of facial anatomy

• Evaluation of soft tissue characteristics

• Assessment of existing facial volume and proportions

• Review of previous aesthetic treatments

• Assessment of contraindications

• Discussion of realistic treatment expectations

• Explanation of potential adverse effects and complications

• Appropriate documented informed consent

Treatment should be individually tailored according to the patient's anatomy, degree of volume loss, tissue characteristics and intended outcome.

The appropriate product volume, administration technique, treatment depth and equipment selection must be determined according to the manufacturer's current Instructions for Use and the practitioner's training.

MONALISA® Hard Type should not be administered using a generic treatment protocol without consideration of individual vascular anatomy and treatment-area risks.

Treatment Review & Maintenance

The supplied product information describes a treatment pathway involving an initial treatment followed by professional reassessment.

A typical clinical review may be considered approximately 2–4 weeks following treatment, according to practitioner protocol and individual patient requirements.

Additional correction should only be considered following appropriate clinical review.

Maintenance requirements will depend on:

• Treatment area

• Product persistence

• Individual anatomy

• Patient metabolism

• Tissue characteristics

• Previous treatment response

• Individual aesthetic objectives

Treatment intervals and product volumes must always be determined through professional assessment and the manufacturer's current guidance.

Results & Longevity

MONALISA® Hard Type is designed to provide an immediate volumising and structural effect following appropriate administration.

Potential treatment outcomes may include:

• Improved facial volume

• Enhanced facial contour

• Improved projection

• Reduction in the appearance of deeper wrinkles and folds

• Improved selected facial asymmetries

• Greater structural definition

• Smoother-looking facial contours

Initial swelling may temporarily influence the appearance of the treated area and should be considered when assessing early results.

As treatment-related swelling subsides, the final contour may become more apparent.

The duration of results varies according to:

• Treatment area

• Product volume

• Administration technique

• Individual metabolism

• Patient age

• Lifestyle factors

• Tissue characteristics

• Individual biological response

No fixed duration of results is guaranteed.

Maintenance treatment may be considered following professional reassessment where appropriate.

Storage & Handling

Store MONALISA® Hard Type according to the manufacturer's current storage recommendations.

To maintain product integrity:

• Keep the product within its original packaging until required.

• Follow the manufacturer's specified storage conditions.

• Protect from inappropriate environmental exposure.

• Inspect the syringe and packaging before use.

• Check the batch number and expiry date.

• Verify product authenticity and traceability.

• Do not use if the sterile packaging is damaged.

• Do not use if the syringe appears compromised.

• Do not use after the stated expiry date.

The product should be handled using appropriate aseptic procedures.

Each syringe is intended for single use only.

Important Information

MONALISA® Hard Type with Lidocaine is intended strictly for use by appropriately qualified and trained medical or aesthetic professionals.

Professional knowledge of the following is essential:

• Facial anatomy

• Facial vascular anatomy

• Dermal filler administration

• Appropriate treatment planes

• Patient selection

• Aseptic technique

• Complication prevention

• Vascular compromise recognition

• Emergency management

• Dermal filler complication management

Patient Assessment & Contraindications

Treatment should only proceed following a full patient consultation, medical assessment and appropriate informed consent.

Treatment suitability must be assessed according to the manufacturer's current Instructions for Use.

Factors requiring particular consideration include:

• Active infection or inflammation within the proposed treatment area

• Known hypersensitivity to Hyaluronic Acid

• Known hypersensitivity to Lidocaine or other product components

• Pregnancy or breastfeeding

• Relevant uncontrolled medical conditions

• Previous filler treatments within the proposed treatment area

• Other contraindications identified during professional assessment

This list is not exhaustive and does not replace the manufacturer's official contraindications.

Potential Side Effects

Temporary treatment-related effects may include:

• Redness

• Swelling

• Bruising

• Tenderness

• Localised discomfort

• Temporary firmness

• Injection-site sensitivity

• Localised irregularity

Serious Complications

More serious complications associated with injectable dermal filler procedures may include:

• Infection

• Vascular compromise or occlusion

• Tissue ischaemia or necrosis

• Delayed inflammatory reactions

• Nodules

• Product migration

• Persistent contour irregularities

• Visual impairment or blindness associated with vascular complications

Practitioners must be appropriately trained in the prevention, recognition and management of filler-related complications, including emergency escalation where required.

Patients should receive appropriate written aftercare information and clear instructions regarding symptoms requiring urgent medical attention.

Always consult the manufacturer's current Instructions for Use for complete indications, contraindications, precautions, warnings, administration guidance and potential adverse events.

Do not use if:

• The sterile packaging is damaged or compromised

• The syringe appears damaged

• The product has passed its expiry date

• Product integrity is in doubt

• Product authenticity cannot be verified

For appropriately qualified professional use only.